Wang Shi-Yao, Huang Zhi-Hang, Duan Rui, Fu Xin-Xin, Qi Jing-Wen, Luo Zi-Jian, Zhang Ying-Dong, Jiang Teng
Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, PR China.
The First School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu Province, PR China.
J Alzheimers Dis. 2025 Apr;104(3):875-885. doi: 10.1177/13872877251320418. Epub 2025 Mar 2.
BackgroundAs a recently identified cytokine, interleukin-34 (IL-34) is predominantly produced by neurons and functions as a modulator for glial functions. Emerging evidence indicates that IL-34 exerted neuroprotective effects in Alzheimer's disease (AD), but the underlying mechanism remained elusive.ObjectiveTo uncover the mechanisms by which IL-34 provides neuroprotection in AD.MethodsUsing senescence-accelerated mouse prone substrain 8 (SAMP8) mice, a well-established model for sporadic AD, we investigated the dynamic changes in brain IL-34 concentrations during AD progression. Afterwards, SAMP8 mice received a 4-week continuous intracerebroventricular infusion of IL-34. Morris water maze test was employed to assess the spatial cognitive functions. Neuronal and synaptic markers, oxidative stress makers, pro-inflammatory cytokines and glial activation markers in the brains of SAMP8 mice were measured. Finally, amyloid-β (Aβ)-stimulated primary microglia, lentivirus-mediated gene knockdown strategy and co-immunoprecipitation assay were utilized to uncover the possible mechanisms by which IL-34 exerted neuroprotection in AD.ResultsIn SAMP8 mice, we revealed that brain IL-34 concentrations gradually decreased during AD progression. A 4-week continuous intracerebroventricular infusion of IL-34 rescued spatial cognitive impairments, ameliorated neuronal and synaptic damage, and suppressed oxidative stress and microglia-mediated inflammation in the brains of SAMP8 mice. Using Aβ-stimulated primary microglia, we demonstrated for the first time that IL-34 suppressed microglial NLRP3 inflammasome activation and pro-inflammatory cytokines release by interacting with triggering receptor expressed on myeloid cells 2 (TREM2), a key regulator of microglial functions.ConclusionsThese findings uncover the mechanisms by which IL-34 provides neuroprotection in AD, indicating that IL-34/TREM2 signaling may represent a novel therapeutic strategy for this devastating disease.
背景
作为一种最近被发现的细胞因子,白细胞介素-34(IL-34)主要由神经元产生,并作为神经胶质细胞功能的调节剂发挥作用。新出现的证据表明,IL-34在阿尔茨海默病(AD)中发挥神经保护作用,但其潜在机制仍不清楚。
目的
揭示IL-34在AD中提供神经保护的机制。
方法
使用衰老加速小鼠易感亚系8(SAMP8)小鼠,这是一种成熟的散发性AD模型,我们研究了AD进展过程中脑内IL-34浓度的动态变化。之后,SAMP8小鼠接受了为期4周的脑室内连续输注IL-34。采用莫里斯水迷宫试验评估空间认知功能。检测SAMP8小鼠脑内的神经元和突触标记物、氧化应激标志物、促炎细胞因子和神经胶质细胞激活标记物。最后,利用淀粉样β(Aβ)刺激的原代小胶质细胞、慢病毒介导的基因敲低策略和免疫共沉淀试验,揭示IL-34在AD中发挥神经保护作用的可能机制。
结果
在SAMP8小鼠中,我们发现脑内IL-34浓度在AD进展过程中逐渐降低。为期4周的脑室内连续输注IL-34挽救了空间认知障碍,改善了神经元和突触损伤,并抑制了SAMP8小鼠脑内的氧化应激和小胶质细胞介导的炎症。利用Aβ刺激的原代小胶质细胞,我们首次证明IL-34通过与髓样细胞表达的触发受体2(TREM2)相互作用,抑制小胶质细胞NLRP3炎性小体激活和促炎细胞因子释放,TREM2是小胶质细胞功能的关键调节因子。
结论
这些发现揭示了IL-34在AD中提供神经保护的机制,表明IL-34/TREM2信号通路可能代表了针对这种毁灭性疾病的一种新的治疗策略。